Oxy210

Oxy210 is a first-in-class small molecule oxysterol derivative that acts as a dual inhibitor of the Hedgehog (Hh) and transforming growth factor-beta (TGF-β) signaling pathways. It has demonstrated potent anti-fibrotic, anti-inflammatory, and lipid-lowering effects in preclinical models. In studies using humanized mouse models of non-alcoholic steatohepatitis (NASH), oral administration of Oxy210 significantly reduced hepatic fibrosis, inflammation, cholesterol accumulation, and improved hypercholesterolemia without apparent toxicity. Mechanistically, it antagonizes both Hh and TGF-β signaling in hepatic stellate cells and exerts direct anti-inflammatory effects in macrophages partly through inhibition of Toll-Like Receptor signaling. Additional benefits observed include reduction in pro-inflammatory cytokines (such as IL-6, TNF-α), inflammasome gene expression (NLRP3), apoptosis in the liver, adipose tissue inflammation, and atherosclerotic lesion formation. Developed by MAX BioPharma for NASH/MASH and related metabolic diseases including atherosclerosis[1][4][5][6].